Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Rigel Pharmaceuticals Provides Business Update

View All

Jan 9, 2020 • 7:30 AM EST

Rigel to Present at the 38th Annual J.P. Morgan Healthcare Conference

Dec 17, 2019 • 5:00 PM EST

Rigel Announces Chief Commercial Officer Transition

Nov 15, 2019 • 7:30 AM EST

Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

January 2020

View Presentation

38th Annual J.P. Morgan Healthcare Conference

View Event View All

Q3 2019

Quarter Ended Sep 30, 2019

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2018

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080